Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLBP-024
- Development stage
- Preclinical
- Lead developer
- HLB Pharma
- Modality
- Small Molecules
- Administration
- Subcutaneous, Intramuscular
01
Overview
HLBP-024 is a long-acting injectable (LAI) formulation developed by HLB Pharma for the prevention of thrombosis. The candidate utilizes HLB Pharma's proprietary SMEB (Smart Microsphere Emulsification & Bio-encapsulation) technology to encapsulate an antithrombotic agent within sustained-release microspheres. This delivery system is designed to provide a controlled, long-term release of the medication, potentially reducing the frequency of administration and improving patient compliance compared to standard oral or short-acting injectable therapies. As of 2024, HLBP-024 is in the formulation research stage of development.
02
Targets
F10 (Factor Xa)
Beyond the preview
Go deeper on HLBP-024.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLBP-024.